Related Experiment Videos
Cold agglutinins: specificity, idiotypy and structural analysis.
G J Silverman1, P P Chen, D A Carson
1Department of Basic and Clinical Research, Research Institute of Scripps Clinic, La Jolla, Calif.
Summary
Cold agglutinins (CAs) are natural autoantibodies. Their precursors are common, potentially explaining their presence in various disorders and association with Epstein-Barr virus infection.
Area of Science:
- Immunology
- Autoimmunity
- Molecular Genetics
Background:
- Cold agglutinins (CAs) are natural autoantibodies with precursors appearing early in development.
- Many CAs utilize specific L chains (germline kv325 gene) and H chains (VHIV gene family).
- CAs may represent an expression of the preimmune antibody repertoire.
Purpose of the Study:
- To investigate the origins and potential role of cold agglutinins in various disorders.
- To explore the association between cold agglutinins, Epstein-Barr virus infection, and lymphoproliferative disorders.
- To understand the genetic basis and transformation of natural autoantibodies into malignancy.
Main Methods:
- Analysis of L chain gene usage (kv325) in cold agglutinin precursors.
- Investigation of cold agglutinin emergence during Epstein-Barr virus infection (in vitro and in vivo).
- Examination of cold agglutinins in lymphoproliferative disorders, including karyotypic analysis of involved lymphocytes.
Main Results:
- Germline kv325 gene-derived L chains are preferentially expressed in CA precursors and during Epstein-Barr virus infection.
- Cold agglutinins can arise independent of antigenic selection, linked to immature B cell expansion.
- In lymphoproliferative disorders, CAs can result from clonal expansion of abnormal lymphocytes.
Conclusions:
- Cold agglutinins likely originate from common precursors and their target epitopes are widespread.
- Epstein-Barr virus infection may promote the expansion of cold agglutinin-producing B cells.
- Antigenic selection can drive the expansion of CA-producing clones, potentially leading to malignancy in lymphoproliferative disorders.